However, it is contraindicated for those with certain health conditions and is far less effective for individuals with methylation impairments
An analysis by the Annals of Internal Medicine published in October 2022 found that the price of GLP-1s would need to drop by 90% to be considered reasonable for use as a first-line therapy
On day 6, probe trials were conducted 1 and 24h post-training
It's a message that industry groups are pushing heavily ahead of this week's meeting
reports consulting/speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Novartis, Menarini-Ricerche, Novo Nordisk, Pfizer, Roche Diagnostics and Sanofi, along with grants paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics
Key points: In the only head-to-head trial, Wegovy produced 15.8% weight loss compared with 6.4% for Saxenda over the same 68-week period Wegovy 7.2 mg (approved January 2026) produces even greater results at 20.7% average weight loss Real-world data from Second Nature shows 19.1% weight loss with semaglutide when combined with behavioural support Semaglutide participants were nearly three times more likely to achieve at least 10% weight loss than liraglutide participants Side effects and tolerability Both medications share a similar side-effect profile, predominantly affecting the gastrointestinal tract